Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EBS 
Emergent Biosolutions Inc (EBS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: EBS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.14% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 496.17M USD | Price to earnings Ratio 3.55 | 1Y Target Price 13.5 |
Price to earnings Ratio 3.55 | 1Y Target Price 13.5 | ||
Volume (30-day avg) 3 | Beta 2.05 | 52 Weeks Range 4.02 - 12.73 | Updated Date 10/13/2025 |
52 Weeks Range 4.02 - 12.73 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.38% | Operating Margin (TTM) 0.35% |
Management Effectiveness
Return on Assets (TTM) 5.03% | Return on Equity (TTM) 30.24% |
Valuation
Trailing PE 3.55 | Forward PE 2.33 | Enterprise Value 890796599 | Price to Sales(TTM) 0.58 |
Enterprise Value 890796599 | Price to Sales(TTM) 0.58 | ||
Enterprise Value to Revenue 1.1 | Enterprise Value to EBITDA 2.59 | Shares Outstanding 53351099 | Shares Floating 51872740 |
Shares Outstanding 53351099 | Shares Floating 51872740 | ||
Percent Insiders 2.84 | Percent Institutions 69.79 |
Upturn AI SWOT
Emergent Biosolutions Inc
Company Overview
History and Background
Emergent BioSolutions Inc. was founded in 1998 as BioPort Corporation. It has evolved from a biodefense company focused on anthrax vaccines to a broader specialty biopharmaceutical company developing and manufacturing products for public health threats.
Core Business Areas
- Anthrax: Development, manufacturing, and sales of anthrax vaccines and treatments.
- Medical Countermeasures: Development and sales of products addressing chemical, biological, radiological, nuclear, and explosive (CBRNE) threats.
- Contract Development and Manufacturing (CDMO): Provides contract manufacturing services for pharmaceutical and biotechnology companies.
- NARCANu00ae Nasal Spray: Development, manufacturing, and sales of NARCANu00ae Nasal Spray to counteract opioid overdoses.
Leadership and Structure
The leadership team includes the CEO, CFO, CSO, and other key executives. The organizational structure includes divisions for each core business area, as well as functional departments such as R&D, manufacturing, and sales.
Top Products and Market Share
Key Offerings
- BioThrax: Anthrax vaccine, primarily sold to the US government. Competitors are limited due to the unique government contract nature. Estimated revenue varies depending on government procurement but is a major contributor to overall revenue.
- NARCANu00ae Nasal Spray: A naloxone nasal spray used to reverse opioid overdoses. Emergent acquired NARCAN in 2023. Competitors include Teva Pharmaceutical Industries (TEVA) and Amphastar Pharmaceuticals (AMPH). Market share varies, but NARCAN is a leading brand.
- AVONCAPu2122: Emergency medication for nerve agent exposure. Sells primarily to the US government.
Market Dynamics
Industry Overview
The specialty biopharmaceutical industry is focused on developing and manufacturing products for specific diseases and public health threats. This market is characterized by high regulatory hurdles, significant R&D investments, and government contracts.
Positioning
Emergent BioSolutions is positioned as a leader in biodefense and public health countermeasures. Its competitive advantages include its established relationship with the US government and its expertise in developing and manufacturing complex biological products.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the billions of dollars, considering government contracts, public health initiatives, and the opioid crisis. Emergent BioSolutions is positioned to capture a significant portion of this market through its established products and pipeline.
Upturn SWOT Analysis
Strengths
- Strong relationship with the US government
- Expertise in developing and manufacturing biodefense products
- Established infrastructure for large-scale manufacturing
- Acquisition of NARCAN provides exposure to opioid overdose market
Weaknesses
- Dependence on government contracts
- History of manufacturing issues and contract delays
- Limited product diversification
- High debt load following acquisition of Adapt Pharma
Opportunities
- Expansion into new therapeutic areas
- Increased government funding for biodefense
- Partnerships with other pharmaceutical companies
- Further penetration of the opioid overdose market
Threats
- Changes in government priorities and funding
- Competition from other biopharmaceutical companies
- Regulatory challenges
- Potential for manufacturing disruptions
Competitors and Market Share
Key Competitors
- SIGA
- GOVX
- CBRX
Competitive Landscape
Emergent BioSolutions faces competition from other biodefense companies and pharmaceutical manufacturers. Its competitive advantages include its established relationships with the government and its expertise in manufacturing.
Major Acquisitions
Adapt Pharma
- Year: 2018
- Acquisition Price (USD millions): 735
- Strategic Rationale: Acquisition of Adapt Pharma gave Emergent the rights to NARCANu00ae Nasal Spray, expanding its portfolio into the opioid overdose market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by government contracts and acquisitions.
Future Projections: Future growth projections depend on securing new contracts, expanding into new markets, and addressing manufacturing challenges. Analyst estimates are varied.
Recent Initiatives: Recent strategic initiatives include restructuring the company to reduce costs and focusing on core business areas.
Summary
Emergent BioSolutions is a key player in biodefense, leveraging strong government relationships and manufacturing expertise. While the acquisition of NARCAN diversified their portfolio, manufacturing challenges and heavy reliance on government contracts remain significant hurdles. Future success hinges on efficient execution and expansion into new therapeutic areas. Strategic restructuring and cost management are crucial for improving financial stability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions can change rapidly, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Emergent Biosolutions Inc
Exchange NYSE | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2006-11-15 | CEO, President & Director Mr. Joseph C. Papa Jr., M.B.A., R.Ph. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 900 | |
Full time employees 900 | |||
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.